Answers are grounded in this paper and cite their sources.
Background: Reliable circulating biomarkers remain clinically important in the evaluation of breast cancer. This cross-sectional study assessed serum caspase-3, carcinoembryonic antigen (CEA), and certain electrolyte parameters in a control group of healthy individuals and breast cancer patients at different clinical stages. Methods: Ninety female participants were divided into Control (n=30), Newly Diagnosed (G1, n=20), and Treated (G2, n=40) groups. Serum Caspase-3, CEA, and electrolytes (Zn2+, Ca2+, Na+, K+) were measured. Blood samples in the treated group were collected after completion of the fourth chemotherapy cycle during routine follow-up visits. No participants were excluded after laboratory analysis due to missing biomarker data. Data were analyzed using ANOVA and ROC curves. A p-value < 0.05 was considered statistically significant. Results: Caspase-3 levels were lowest in the newly diagnosed group (G1), whereas treated patients (G2) showed higher values than G1. One-way ANOVA demonstrated a statistically significant difference among the study groups for Caspase-3 (p = 0.004). CEA concentrations also differed significantly between groups (p = 0.002). Significant differences were observed for Zn²⁺ (p < 0.001), Ca²⁺ (p < 0.0001), Na⁺ (p < 0.001), and K⁺ (p < 0.0001). ROC analysis indicated moderate diagnostic performance for CEA (AUC = 0.7537). Conclusion: Between-group differences were observed in serum Caspase-3, CEA, and selected electrolyte levels.
No takes yet. Share an insight, caveat, or question.
Shammari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: